Immunoclin Corp (IMCL) 0.1200 $IMCL
Latest Studies and Clinical Trials Lead to Compelling Developments Indicating Cannabinoids May Contain Significant Analgesic Effects in Treating Various Diseases & Conditions
PR Newswire - Wed Dec 16, 9:00AM CST
Comprehensive studies and research efforts are lending support that medical marijuana & cannabinoids may be safe, demonstrate a modest analgesic effect and could provide a reasonable treatment option for treatment chronic non-cancer pain and other ailments & diseases. Today's leading companies with recent developments of interest are Cannabis Science, Inc. (OTC: CBIS), Compass Diversified Holdings (NYSE: CODI), NEMUS Bioscience, Inc. (OTC: NMUS), GW Pharmaceuticals (NASDAQ: GWPH) and Insys Therapeutics, Inc. (NASDAQ: INSY)
INSY: 15.65 (+0.01), CODI: 17.02 (-0.03), GWPH: 94.32 (unch)
After Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a Phase I Human Study in Europe
Marketwired - Tue Dec 15, 6:54AM CST
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced that it has entered into a comprehensive clinical drug development to focus on delivering GMP quality pre-clinical data to enable entry of CS-NEURO-1 into a Phase I human study in Europe with ImmunoClin (OTCQB: IMCL).
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 with AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche & Pfizer Dominating
M2 - Thu Nov 12, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4z56z7/global_nonsmall) has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019. The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report includes a discussion of the key vendors operating in this market. The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period. According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients. Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market. Key vendors - AstraZeneca - Celgene - Eli Lilly - F. Hoffmann-La Roche - Pfizer Other prominent vendors - Abbvie - Aetna - Agennix - Amgen - BetaPharma - Bionumerik Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - CBT Pharma - Celldex Therapeutics - Dainippon Pharma - Eisai Pharmaceuticals - GlaxoSmithKline - Helsinn - IMClone Systems - IsisPharma - Kadmon - Kyowa Hakko Kirin - MabVax Therapeutics - Merck - Novartis - OncoGenex - OSI Pharmaceuticals - Peregrine - Pierre Fabre - Qiagen - Sanofi - Synta Pharmaceuticals - Teva Pharmaceuticals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Product profiles Part 05: Introduction Part 06: Disease overview Part 07: Pipeline portfolio Part 08: Market landscape Part 09: Market segmentation by molecule type Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis Part 19: Appendix For more information visit http://www.researchandmarkets.com/research/4z...l_nonsmall
SNTA: 0.34 (+0.07), MRK: 58.66 (+0.23), CLDX: 4.62 (-0.10), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), NVS: 83.26 (+1.18), CELGZ: 1.16 (-0.01)
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Subsidiary of ImmunoClin Corporation (IMCL) receives controlled drug license in the United Kingdom
PR Newswire - Thu Apr 02, 11:51AM CDT
ImmunoClin Corporation (OTC Markets: IMCL), a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.
Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014
PR Newswire Europe - Wed Nov 26, 8:01PM CST
Research and Markets ( http://www.researchandmarkets.com/research/vk...ic_review) has announced the addition of the "Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014" [http://www.researchandmarkets.com/research/vk8bgt/strategic_review ] report to their offering.
Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr. Dorothy Bray As Scientific Advisory Board Chair And Clinical Development Consultant
PR Newswire - Thu Nov 06, 5:45AM CST
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that some major corporate changes are taking place, allowing the Company to better position itself to face the continuing evolution of the industry and ongoing and incoming projects and initiatives.
Latest Studies and Clinical Trials Lead to Compelling Developments Indicating Cannabinoids May Contain Significant Analgesic Effects in Treating Various Diseases & Conditions
PR Newswire - Wed Dec 16, 9:00AM CST
Comprehensive studies and research efforts are lending support that medical marijuana & cannabinoids may be safe, demonstrate a modest analgesic effect and could provide a reasonable treatment option for treatment chronic non-cancer pain and other ailments & diseases. Today's leading companies with recent developments of interest are Cannabis Science, Inc. (OTC: CBIS), Compass Diversified Holdings (NYSE: CODI), NEMUS Bioscience, Inc. (OTC: NMUS), GW Pharmaceuticals (NASDAQ: GWPH) and Insys Therapeutics, Inc. (NASDAQ: INSY)
INSY: 15.65 (+0.01), CODI: 17.02 (-0.03), GWPH: 94.32 (unch)
After Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a Phase I Human Study in Europe
Marketwired - Tue Dec 15, 6:54AM CST
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced that it has entered into a comprehensive clinical drug development to focus on delivering GMP quality pre-clinical data to enable entry of CS-NEURO-1 into a Phase I human study in Europe with ImmunoClin (OTCQB: IMCL).
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 with AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche & Pfizer Dominating
M2 - Thu Nov 12, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4z56z7/global_nonsmall) has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019. The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report includes a discussion of the key vendors operating in this market. The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period. According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients. Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market. Key vendors - AstraZeneca - Celgene - Eli Lilly - F. Hoffmann-La Roche - Pfizer Other prominent vendors - Abbvie - Aetna - Agennix - Amgen - BetaPharma - Bionumerik Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - CBT Pharma - Celldex Therapeutics - Dainippon Pharma - Eisai Pharmaceuticals - GlaxoSmithKline - Helsinn - IMClone Systems - IsisPharma - Kadmon - Kyowa Hakko Kirin - MabVax Therapeutics - Merck - Novartis - OncoGenex - OSI Pharmaceuticals - Peregrine - Pierre Fabre - Qiagen - Sanofi - Synta Pharmaceuticals - Teva Pharmaceuticals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Product profiles Part 05: Introduction Part 06: Disease overview Part 07: Pipeline portfolio Part 08: Market landscape Part 09: Market segmentation by molecule type Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis Part 19: Appendix For more information visit http://www.researchandmarkets.com/research/4z...l_nonsmall
SNTA: 0.34 (+0.07), MRK: 58.66 (+0.23), CLDX: 4.62 (-0.10), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), NVS: 83.26 (+1.18), CELGZ: 1.16 (-0.01)
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Subsidiary of ImmunoClin Corporation (IMCL) receives controlled drug license in the United Kingdom
PR Newswire - Thu Apr 02, 11:51AM CDT
ImmunoClin Corporation (OTC Markets: IMCL), a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.
Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014
PR Newswire Europe - Wed Nov 26, 8:01PM CST
Research and Markets ( http://www.researchandmarkets.com/research/vk...ic_review) has announced the addition of the "Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014" [http://www.researchandmarkets.com/research/vk8bgt/strategic_review ] report to their offering.
Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr. Dorothy Bray As Scientific Advisory Board Chair And Clinical Development Consultant
PR Newswire - Thu Nov 06, 5:45AM CST
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that some major corporate changes are taking place, allowing the Company to better position itself to face the continuing evolution of the industry and ongoing and incoming projects and initiatives.
